Icure Pharmaceutical Incorporation

KOSDAQ:A175250 Stock Report

Market Cap: ₩73.3b

Icure Pharmaceutical Incorporation Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

No updates

Recent updates

Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Sep 04
Icure Pharmaceutical Incorporation (KOSDAQ:175250) May Have Run Too Fast Too Soon With Recent 26% Price Plummet

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

Aug 28
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) A Risky Investment?

What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Jul 21
What Icure Pharmaceutical Incorporation's (KOSDAQ:175250) 27% Share Price Gain Is Not Telling You

Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

May 31
Icure Pharmaceutical Incorporation (KOSDAQ:175250) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected

Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

May 27
Is Icure Pharmaceutical Incorporation (KOSDAQ:175250) Using Debt In A Risky Way?

Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

Mar 07
Some Shareholders Feeling Restless Over Icure Pharmaceutical Incorporation's (KOSDAQ:175250) P/S Ratio

We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

Dec 25
We Think Icure Pharmaceutical Incorporation (KOSDAQ:175250) Has A Fair Chunk Of Debt

CEO

Icure Pharmaceutical Incorporation has no CEO, or we have no data on them.